STL Index for: Brian Berman
Imiquimod 3.75% cream has recently been approved by both the FDA and Health Canada for the treatment of external genital warts. This article is an overview of EGW, phase 3 clinical trials leading to the approval of imiquimod 3.75% cream, and comparison with imiquimod 5% cream.
Imiquimod is the first of a new class of drugs to emerge in the treatment of various dermatologic disorders. As an immune response modifier, it has been shown to have potent antiviral and antitumor properties through the stimulation of innate and cell mediated immune pathways.